Urolithin A and Lung Health: What the Early Research Shows
Key takeaways
- The lungs are among the most oxygen- and oxidant-exposed organs in the body, which places heavy demand on cellular mitochondria.
- In PRECLINICAL models of lung injury, standardized Urolithin A reduced mitochondrial dysfunction and influenced immune-cell behavior.
- A key proposed mechanism is activation of PINK1/PRKN mitophagy, the pathway that tags and clears damaged mitochondria.
- Researchers have even explored inhalable formulations of a Urolithin A-type mitophagy activator for direct lung delivery — a sign of scientific interest, not an available product.
- There are no HUMAN trials on Urolithin A and lung function; any respiratory benefit is unproven in people.
Of all your organs, the lungs live on the front line. With every breath they take in roughly 21% oxygen along with whatever else is in the air — pollutants, smoke, allergens, pathogens. Oxygen is essential, but it is also reactive, and the cells lining your airways and air sacs must constantly manage the oxidative byproducts of their own work. That job runs through mitochondria, which is why a mitochondria-focused compound like Urolithin A has started to appear in early lung research. Here is a careful, evidence-graded look at what scientists have actually found.
Why would a mitochondrial compound matter for the lungs?
Lung tissue is densely populated with mitochondria. Alveolar cells, airway epithelium, and the immune cells that patrol the lungs all depend on mitochondrial energy to maintain the barrier, clear debris, and mount defenses. At the same time, the lung's constant exposure to inhaled oxidants makes it unusually prone to mitochondrial wear and tear. When damaged mitochondria accumulate, they leak reactive oxygen species and inflammatory signals, which can amplify tissue stress.
This is where mitophagy enters the picture. Mitophagy is the quality-control process that identifies failing mitochondria and recycles them before they cause trouble. Urolithin A's best-documented action is precisely this: in the foundational work that put it on the map, it was shown to induce mitophagy and improve mitochondrial function (PRECLINICAL; Nature Medicine, 2016). That mechanism, applied to a highly oxidant-exposed organ, is what makes the lung an obvious place for researchers to look next.
What has preclinical lung research found?
The lung studies so far use models of acute injury — situations where the lungs face an intense, defined insult — rather than everyday respiratory aging. That distinction matters when interpreting the results.
| Preclinical model | What was observed with Urolithin A | Evidence grade |
|---|---|---|
| Sepsis-induced acute lung injury (rodent) | Reduced mitochondrial dysfunction and shifted macrophage polarization toward a less inflammatory profile | PRECLINICAL |
| Radiation pneumonitis (rodent) | Alleviated lung inflammation by activating PINK1/PRKN-mediated mitophagy | PRECLINICAL |
| Human lung cell cultures + inhalable formulation | A spray-dried micro/nanoparticle mitophagy activator was characterized for targeted lung delivery and aerosol performance | PRECLINICAL / in vitro |
In a model of sepsis-driven lung injury, Urolithin A supplementation reduced mitochondrial dysfunction and modulated macrophage polarization (PRECLINICAL) — meaning it nudged the lung's resident immune cells away from a purely inflammatory state. In a separate model of radiation-induced lung inflammation, researchers reported that Urolithin A alleviated pneumonitis by activating PINK1/PRKN-mediated mitophagy (PRECLINICAL), directly implicating the mitochondrial-cleanup pathway. Interest has gone far enough that a team designed and characterized inhalable spray-dried microparticles of a mitophagy activator for targeted lung delivery (PRECLINICAL / in vitro). A broader systematic review of urolithin research places these lung findings within the compound's wide investigational footprint while stressing that most evidence remains preclinical (review).
How might Urolithin A act in lung tissue?
Clearing damaged mitochondria (mitophagy)
The recurring mechanism across these studies is PINK1/PRKN mitophagy. PINK1 and Parkin (PRKN) are proteins that tag depolarized, failing mitochondria for recycling. By helping this system keep pace, Urolithin A appears — in animals — to limit the buildup of dysfunctional mitochondria that would otherwise fuel oxidative stress and inflammation in injured lungs.
Influencing immune-cell behavior
Alveolar macrophages can adopt a pro-inflammatory ("M1-like") or a resolving ("M2-like") profile. The sepsis-injury study reported that Urolithin A shifted this balance toward resolution, which fits the compound's broader association with a more balanced inflammatory tone at the cellular level.
Supporting the cellular energy barrier
Healthy mitochondria help the airway and alveolar lining maintain its barrier function. In theory, preserving mitochondrial quality supports the structural cells that keep the lung's delicate gas-exchange surface intact — though this remains a mechanistic hypothesis rather than a measured human outcome.
What does this mean for you?
The honest answer is that lung research on Urolithin A is early and entirely preclinical. The studies use acute-injury models in animals, not healthy people going about daily life, and none measured lung function, breathing capacity, or respiratory disease outcomes in humans. You should not take Urolithin A expecting to protect or improve your lungs — that claim is not supported by human evidence.
What the human literature does establish is that Urolithin A is safe and well tolerated while improving markers of mitochondrial and cellular health (HUMAN; Nature Metabolism, 2019), and that it can support muscle endurance and mitochondrial biomarkers in older adults (HUMAN; JAMA Network Open, 2022). Those are whole-body cellular-energy findings, and the lung work is best understood as researchers asking whether that same mitophagy mechanism extends to other organs.
For your lungs specifically, the proven playbook is unchanged: don't smoke or vape, limit exposure to air pollution where you can, stay active to maintain cardiorespiratory fitness, and keep up with recommended vaccinations and screenings. A daily SOMA Urolithin A gummy can be part of a general cellular-health routine for people already interested in mitochondrial support — with clear-eyed expectations about where the respiratory science currently stands.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →Frequently asked questions
Does Urolithin A improve lung function?
There is no human evidence that Urolithin A improves lung function or breathing. The existing lung research is preclinical and focused on animal injury models and the mitophagy mechanism, not measured respiratory outcomes in people.
Can Urolithin A help if I have a respiratory condition?
Urolithin A is not a treatment for any respiratory or lung condition. If you have a diagnosed lung issue, follow your healthcare provider's guidance; do not substitute a supplement for medical care.
Why are scientists studying Urolithin A and the lungs?
The lungs are heavily exposed to oxidants and rich in mitochondria. Because Urolithin A activates mitophagy — the recycling of damaged mitochondria — researchers are exploring whether that mechanism is relevant to lung-cell biology.
Is there an inhalable Urolithin A product?
No consumer inhalable product exists. One research group has characterized an experimental inhalable formulation of a mitophagy activator in the laboratory, which reflects scientific interest only.
Is Urolithin A safe to take every day?
Human trials report that Urolithin A is well tolerated at studied doses. As always, check with your healthcare provider before starting, particularly if you are pregnant, nursing, or on medication.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.